A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors

被引:8
|
作者
Oba, Atsushi [1 ]
Kudo, Atsushi [1 ]
Akahoshi, Keiichi [1 ]
Kishino, Mitsuhiro [2 ]
Akashi, Takumi [3 ]
Katsuta, Eriko [1 ]
Iwao, Yasuhito [1 ]
Ono, Hiroaki [1 ]
Mitsunori, Yusuke [1 ]
Ban, Daisuke [1 ]
Tanaka, Shinji [4 ]
Eishi, Yoshinobu [3 ]
Tateishi, Ukihide [2 ]
Tanabe, Minoru [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary & Pancreat Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan
[2] Tokyo Med & Dent Univ, Grad Sch Med, Dept Radiol, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med, Dept Human Pathol, Tokyo, Japan
[4] Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Oncol, Tokyo, Japan
关键词
Pancreatic neuroendocrine tumors; Morphological classification; Multi-detector computed tomography; WHO; 2010; classification; ENETS TNM classification; AJCC TNM classification; Single nodular with extra-nodular growth; Confluent multinodular; HEPATOCELLULAR-CARCINOMA; COMPUTED-TOMOGRAPHY; PROGNOSTIC-FACTORS; CT; EXPRESSION; NEOPLASMS; SYSTEM;
D O I
10.1007/s00535-017-1349-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A novel morphological classification using resected specimens predicted malignant potential and prognosis in patients with pancreatic neuroendocrine tumors (P-NETs). The aim of this study was to examine the predictive ability of morphological diagnoses made using non-invasive multi-detector computed tomography (MDCT) in P-NETs. Methods Between 2002 and 2015, 154 patients were diagnosed with P-NETs at the Tokyo Medical and Dental University, and 82 patients who underwent surgical treatment were enrolled. The primary tumors were classified by MDCT into three types: Type I, simple nodular tumor; Type II, simple nodular tumor with extra-nodular growth; and Type III, confluent multinodular tumor. Patients were stratified by 15 clinical specialists according to classification and without any other clinical or pathological information. Clinicopathological features and patient survival were reviewed retrospectively. Results The mean observation time was 1004 days. Forty-six, 22, and 14 patients had Type I, II, and III tumors, respectively. Morphological classification was significantly correlated with advanced features such as tumor size, Ki-67 index, and synchronous liver metastasis (p < 0.001 for all). There were significant differences between all three tumor types as judged by ENETS TNM classification (p < 0.001), AJCC TNM classification (p = 0.046), WHO 2004 classification (p < 0.001), and WHO 2010 classification (p < 0.001). Five-year progression-free survival (PFS) rates for patients with Type I, II, and III tumors were 97, 43, and 31%, respectively (I vs. II, p < 0.001; I vs. III, p < 0.001; II vs. III, p = 0.017). Multivariate analysis revealed Type II/III tumors and synchronous liver metastasis to be independent risk factors for poor PFS. Conclusion A novel simple morphological classification system would predict Type II and III tumors that may have higher malignant potential than Type I tumors.
引用
收藏
页码:1140 / 1146
页数:7
相关论文
共 50 条
  • [1] A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors
    Atsushi Oba
    Atsushi Kudo
    Keiichi Akahoshi
    Mitsuhiro Kishino
    Takumi Akashi
    Eriko Katsuta
    Yasuhito Iwao
    Hiroaki Ono
    Yusuke Mitsunori
    Daisuke Ban
    Shinji Tanaka
    Yoshinobu Eishi
    Ukihide Tateishi
    Minoru Tanabe
    Journal of Gastroenterology, 2017, 52 : 1140 - 1146
  • [2] Molecular Basis of Pancreatic Neuroendocrine Tumors
    Maluchenko, Alesia
    Maksimov, Denis
    Antysheva, Zoia
    Krupinova, Julia
    Avsievich, Ekaterina
    Glazova, Olga
    Bodunova, Natalia
    Karnaukhov, Nikolay
    Feidorov, Ilia
    Salimgereeva, Diana
    Voloshin, Mark
    Volchkov, Pavel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [3] Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors
    Deguelte, S.
    de Mestier, L.
    Hentic, O.
    Cros, J.
    Lebtahi, R.
    Hammel, P.
    Kianmanesh, R.
    JOURNAL OF VISCERAL SURGERY, 2018, 155 (02) : 117 - 125
  • [4] Pancreatic Neuroendocrine Tumors
    Chorna, N.
    Lukashenko, A.
    Kolesnik, O.
    Ostapenko, Y.
    Patsko, V
    NEUROENDOCRINOLOGY, 2019, 108 : 239 - 239
  • [5] Multimodality Imaging of the Pancreatic Neuroendocrine Tumors
    Singh, Amandeep
    Hines, John J.
    Friedman, Barak
    SEMINARS IN ULTRASOUND CT AND MRI, 2019, 40 (06) : 469 - 482
  • [6] Pancreatic neuroendocrine tumors
    Ruszniewski, Philippe
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2024, 208 (04): : 480 - 492
  • [7] Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm
    Katsuta, Eriko
    Kudo, Atsushi
    Akashi, Takumi
    Mitsunori, Yusuke
    Matsumura, Satoshi
    Aihara, Arihiro
    Ban, Daisuke
    Ochiai, Takanori
    Tanaka, Shinji
    Eishi, Yoshinobu
    Tanabe, Minoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (06) : 1299 - 1306
  • [8] Pancreatic Neuroendocrine Tumors Computed Tomography Enhancement, But Not Histological Grade, Correlates With Tumor Aggression
    Yano, Motoyo
    Misra, Sunil
    Carpenter, Danielle H.
    Salter, Amber
    Hildebolt, Charles F.
    PANCREAS, 2017, 46 (10) : 1366 - 1372
  • [9] Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?
    Toshima, Fumihito
    Inoue, Dai
    Komori, Takahiro
    Yoshida, Kotaro
    Yoneda, Norihide
    Minami, Tetsuya
    Matsui, Osamu
    Ikeda, Hiroko
    Gabata, Toshifumi
    JAPANESE JOURNAL OF RADIOLOGY, 2017, 35 (05) : 242 - 253
  • [10] Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential
    Camilli, Massimiliano
    Papadimitriou, Konstantinos
    Nogueira, Amanda
    Incorvaia, Lorena
    Galvano, Antonio
    D'Antonio, Federica
    Ferri, Jose
    Santini, Daniele
    Silvestris, Nicola
    Russo, Antonio
    Peeters, Marc
    Rolfo, Christian
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (05) : 471 - 478